Multiple myeloma

The PBS subsidises elotuzumab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma.

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with elotuzumab, lenalidomide, pomalidomide and selinexor under the National Health Act 1953, section 100 for patients with multiple myeloma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing elotuzumab, lenalidomide, pomalidomide and selinexor.

Section 100 arrangements

Elotuzumab, lenalidomide, pomalidomide and selinexor

These items are only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public hospital.

These items aren’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Lenalidomide

Applying for initial treatment as monotherapy for newly diagnosed disease

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as monotherapy to treat newly diagnosed multiple myeloma can be made either in:

All written applications must include the completed:

Applying for initial treatment as dual therapy for newly diagnosed disease

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as dual therapy to treat newly diagnosed multiple myeloma can be made either in:

All written applications must include the completed:

Applying for initial treatment as triple therapy for newly diagnosed disease

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as triple therapy to treat newly diagnosed multiple myeloma can be made either in:

All written applications must include the completed:

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

Applying for initial treatment for progressive disease

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide to treat progressive multiple myeloma can be made either in:

All written applications must include the completed:

Applying for continuing treatment for progressive disease

Applications for continuing authority approval to prescribe PBS-subsidised lenalidomide to treat multiple myeloma can be made either:

Pomalidomide

Applying for initial treatment as dual therapy

Applications for initial authority approval to prescribe PBS-subsided pomalidomide as dual therapy to treat multiple myeloma can be made either in:

All written applications must include the completed:

Applying for initial treatment as triple therapy

Applications for initial authority approval to prescribe PBS-subsidised pomalidomide as triple therapy to treat multiple myeloma can be made either:

Applying for continuing treatment as dual therapy

Applications for continuing authority approval to prescribe PBS-subsidised pomalidomide as dual therapy to treat multiple myeloma can be made either:

Applying for continuing treatment as triple therapy

Applications for continuing authority approval to prescribe PBS-subsidised pomalidomide as triple therapy to treat multiple myeloma can be made either:

Elotuzumab

Applying for initial treatment as triple therapy

Applications for initial authority approval to prescribe PBS-subsidised elotuzumab as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

Applying for continuing treatment as triple therapy

Applications for continuing authority approval to prescribe PBS-subsidised elotuzumab as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

Selinexor

Applying for initial treatment as dual therapy

Applications for initial authority approval to prescribe PBS-subsidised selinexor as dual therapy to treat relapsed and/or refractory multiple myeloma can be made either:

Applying for continuing treatment as dual therapy

Applications for continuing authority approval to prescribe PBS-subsidised selinexor as dual therapy to treat relapsed and/or refractory multiple myeloma can be made either:

Applying for initial treatment as triple therapy

Applications for initial authority approval to prescribe PBS-subsidised selinexor as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

Applying for continuing treatment as triple therapy

Applications for continuing authority approval to prescribe PBS-subsidised selinexor as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

Applications for continuing authority approval to prescribe PBS-subsidised lenalidomide as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 17 June 2024.
QC 32781